68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

68Ga-NYM096 PET/CT and 177Lu-NYM096

Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER